Literature DB >> 24080152

Cutaneous allodynia as a predictor of migraine chronification.

Mark A Louter1, Johanneke E Bosker, Willebrordus P J van Oosterhout, Erik W van Zwet, Frans G Zitman, Michel D Ferrari, Gisela M Terwindt.   

Abstract

Cutaneous allodynia is a common feature accompanying migraine attacks and considered a clinical marker for central sensitization. In a longitudinal study, we wanted to investigate if allodynia in migraine patients is a predictor of increasing frequency of migraine days. We included 3029 well-defined, web-based migraine patients (86% female, mean age 42.8 ± 11.4 years, 61% migraine without aura). Questionnaires on migraine characteristics (including allodynia), depression and demographic factors were applied. The number of migraine days was measured twice. Multivariate regression models were used, with correction for other factors that are involved in the relation between allodynia and the number of migraine attacks or migraine days, with specific focus on depression. Of all 2331 eligible migraine patients, 1624 (70%) had allodynia. Lifetime depression was an independent risk factor for allodynia (odds ratio 1.52, 95% confidence interval 1.26-1.84), as well as female gender, low age at onset, and high migraine attack frequency. Analysis of the longitudinal data (in migraineurs with a follow-up period of >6 months) showed that, apart from the known risk factors (low age at onset, high baseline number of migraine days, and depression), allodynia was an independent predictor for increase in number of migraine days over a mean follow-up period of 93 ± 30 weeks (median 103 weeks, range 26-160 weeks). Cutaneous allodynia is a risk factor for migraine chronification and may warrant preventive treatment strategies.

Entities:  

Keywords:  chronic migraine; cutaneous allodynia; depression; medication overuse; migraine

Mesh:

Year:  2013        PMID: 24080152     DOI: 10.1093/brain/awt251

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  68 in total

1.  Clinical significance of sensory hypersensitivities in migraine patients: does allodynia have a priority on it?

Authors:  Jong-Geun Seo; Sung-Pa Park
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

2.  Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.

Authors:  Gülşen Kocaman; Neşe Kahraman; Banu Gürkan Köseoğlu; Başar Bilgiç; Zeliha Matur; Mustafa Ertaş; Yeşim Gülşen; Betül Baykan Baykal
Journal:  Noro Psikiyatr Ars       Date:  2018-07-06       Impact factor: 1.339

3.  Migraine Subclassification via a Data-Driven Automated Approach Using Multimodality Factor Mixture Modeling of Brain Structure Measurements.

Authors:  Todd J Schwedt; Bing Si; Jing Li; Teresa Wu; Catherine D Chong
Journal:  Headache       Date:  2017-06-19       Impact factor: 5.887

4.  Cooperativity between remote sites of ectopic spiking allows afterdischarge to be initiated and maintained at different locations.

Authors:  Jay S Coggan; Terrence J Sejnowski; Steven A Prescott
Journal:  J Comput Neurosci       Date:  2015-05-01       Impact factor: 1.621

5.  Identification of Allodynic Migraine Patients with the Turkish Version of the Allodynia Symptom Checklist: Reliability and Consistency Study.

Authors:  Osman Özgür Yalin; Derya Uludüz; Mehmet Ali Sungur; Hande Sart; Aynur Özge
Journal:  Noro Psikiyatr Ars       Date:  2016-04-15       Impact factor: 1.339

Review 6.  Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.

Authors:  Licia Grazzi; Eleonora Grignani; Domenico D'Amico; Emanuela Sansone; Alberto Raggi
Journal:  Curr Pain Headache Rep       Date:  2018-08-27

Review 7.  Risk factors of chronic daily headache or chronic migraine.

Authors:  Soo-Jin Cho; Min Kyung Chu
Journal:  Curr Pain Headache Rep       Date:  2015-01

8.  Clinical Pain Catastrophizing in Women With Migraine and Obesity.

Authors:  Dale S Bond; Dawn C Buse; Richard B Lipton; J Graham Thomas; Lucille Rathier; Julie Roth; Jelena M Pavlovic; E Whitney Evans; Rena R Wing
Journal:  Headache       Date:  2015-06-18       Impact factor: 5.887

9.  Effects of systemic inhibitors of acid-sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.

Authors:  Clément Verkest; Emilie Piquet; Sylvie Diochot; Mélodie Dauvois; Michel Lanteri-Minet; Eric Lingueglia; Anne Baron
Journal:  Br J Pharmacol       Date:  2018-09-22       Impact factor: 8.739

10.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.